SELP and Schnyder corneal dystrophy: Crizanlizumab (SelG1) is a humanized anti-P-selectin antibody that, in a study to assess safety and impact of SelG1 with or without HU therapy in SCD patients with pain crises (SUSTAIN), was shown to be effective in reducing VOC frequency and acute chest syndrome [173].